Physician profile
John A Baker
NPI 1548225519
$19,844.73
in general payments reported to CMS, 2019-2025
16 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,877 · 2021: $782 · 2022: $204 · 2023: $352 · 2024: $333 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,334 · Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,333.63 |
| Food and Beverage | $717.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $15,794.35 | 2019-2024 | Perseris |
| Siemens Medical Solutions USA, INC. | $1,364.97 | 2022-2025 | Atellica Ch 930 Analyzer, Atellica Im 1300 Analyzer |
| Otsuka America Pharmaceutical, INC. | $543.58 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $477.65 | 2019-2020 | |
| Lundbeck LLC | $239.94 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $231.09 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.56 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $188.30 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $187.61 | 2019-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $166.15 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Allergan, INC. | $131.44 | 2019-2020 | |
| Abbvie INC. | $88.64 | 2021-2024 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $82.67 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $66.15 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $60.63 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.